Consultation: Formulary Amendments October 2023

The North East and North Cumbria (NENC) Medicines Committee are seeking system-wide views on adoption of the proposed formulary amendments in the attached consultation document

All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.

Please note

1.    The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to nuth.nyrdtc.rxsupp@nhs.net

2.     This consultation closes at 5pm on Tuesday 12th December 2023

Name *

Email *

Email

Confirm Email

Job title *

Employer *

Locality

Are you responding on behalf of an organisation or as an individual? *

• On behalf of an organisation or organisational leader
• As an individual

Please specify who you are responding for, including job title and organisation as appropriate *

1a. Can your organisation provide access to Pegunigalsidase alfa for treating Fabry disease, as recommended in NICE TA915, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

1b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

1c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

—————————————————————————————————————

2a. Can your organisation provide access to Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable, as recommended in NICE TA917, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

2b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

2c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

—————————————————————————————————————

3a. Can your organisation provide access to Rimegepant for treating migraine, as recommended in NICE TA919, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

3b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

3c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

—————————————————————————————————————

4a. Can your organisation provide access to Ruxolitinib for treating polycythaemia vera, as recommended in NICE TA921, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

4b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

4c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

—————————————————————————————————————

5a. Can your organisation provide access to Daridorexant for treating long-term insomnia, as recommended in NICE TA922, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

5b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

5c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

—————————————————————————————————————

6a. Can your organisation provide access to Tirzepatide for treating type 2 diabetes, as recommended in NICE TA924, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

6b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

6c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

—————————————————————————————————————

7a. NICE did not recommend Baricitinib for treating severe alopecia areata in TA926, so it will be added to the Not Approved list in this indication. Does this create any clinical or commissioning problems? *

• Yes (please specify below)
• No
• Not applicable

7b. What issues would lack of access create? If a specific patient group requires access, please define it and estimate the number of people affected

Do you have any additional comments?

Submit